Mankind Pharma Limited (BOM:543904)

Mankind Pharma Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	5,545	3,820	3,048	3,025	1,672
Short-Term Investments	16,908	7,464	1,413	1,023	5,311
Trading Asset Securities	-	22,581	10,755	8,745	13,062
Cash & Short-Term Investments	22,453	33,865	15,216	12,793	20,045
Cash Growth	-33.70%	122.56%	18.94%	-36.18%	84.76%
Accounts Receivable	15,383	8,483	5,764	3,882	3,306
Other Receivables	-	438.13	321.02	347.23	698.18
Receivables	15,423	8,950	6,102	4,241	4,188
Inventory	20,937	15,535	14,985	17,602	11,835
Prepaid Expenses	-	603.9	331.6	1,360	369.43
Other Current Assets	11,069	6,729	6,645	8,072	2,628
Total Current Assets	69,883	65,682	43,279	44,068	39,066
Property, Plant & Equipment	32,140	31,387	30,170	23,896	19,917
Long-Term Investments	3,511	3,111	3,578	2,404	2,097
Goodwill	64,926	200.23	200.23	204.42	204.42
Other Intangible Assets	101,236	16,630	17,584	18,742	187.62
Long-Term Deferred Tax Assets	1,079	803.98	297.77	392.86	490.11
Other Long-Term Assets	4,821	1,818	2,046	1,770	1,763
Total Assets	277,595	119,633	97,154	91,477	63,726
Accounts Payable	11,334	11,030	10,082	10,764	6,670
Accrued Expenses	-	2,228	1,710	2,598	1,287
Short-Term Debt	-	1,515	1,150	8,052	1,973
Current Portion of Long-Term Debt	29,568	196.96	244.68	242.47	185.02
Current Portion of Leases	143.9	34.23	25.57	20.57	16.22
Current Income Taxes Payable	180.8	463.79	462.56	150.9	110.85
Current Unearned Revenue	-	1,859	1,662	1,394	148.34
Other Current Liabilities	15,409	3,871	3,294	3,013	3,144
Total Current Liabilities	56,636	21,197	18,631	26,235	13,534
Long-Term Debt	55,262	248.68	231.47	491.94	576.7
Long-Term Leases	140.3	77.14	51.78	29.9	45.11
Long-Term Unearned Revenue	200	229.62	254.95	201.54	78.87
Long-Term Deferred Tax Liabilities	18,125	890.69	773.12	556.21	130.32
Other Long-Term Liabilities	-	-	-	-	10
Total Liabilities	131,914	23,875	20,922	28,314	15,097
Common Stock	412.6	400.59	400.59	400.59	400.59
Additional Paid-In Capital	-	421.17	421.17	421.17	421.17
Retained Earnings	-	101,566	82,499	69,729	55,413
Comprehensive Income & Other	142,911	-8,757	-8,969	-8,999	-9,014
Total Common Equity	143,324	93,631	74,352	61,552	47,220
Minority Interest	2,358	2,127	1,881	1,611	1,409
Shareholders' Equity	145,682	95,758	76,233	63,163	48,629
Total Liabilities & Equity	277,595	119,633	97,154	91,477	63,726
Total Debt	85,115	2,072	1,704	8,836	2,796
Net Cash (Debt)	-62,661	31,793	13,512	3,957	17,249
Net Cash Growth	-	135.29%	241.51%	-77.06%	81.29%
Net Cash Per Share	-154.85	79.25	33.73	9.88	43.06
Filing Date Shares Outstanding	412.52	400.64	400.59	400.59	400.59
Total Common Shares Outstanding	412.52	400.59	400.59	400.59	400.59
Working Capital	13,247	44,485	24,647	17,834	25,532
Book Value Per Share	347.44	233.73	185.61	153.65	117.88
Tangible Book Value	-22,838	76,800	56,568	42,606	46,828
Tangible Book Value Per Share	-55.36	191.72	141.21	106.36	116.90
Land	-	3,530	3,528	2,435	2,414
Buildings	-	12,487	10,460	5,863	5,750
Machinery	-	21,504	17,352	13,921	11,846
Construction In Progress	-	2,071	4,932	6,699	3,716
Leasehold Improvements	-	88.68	88.74	64.47	60.1

Source: S&P Global Market Intelligence. Standard template. Financial Sources.